Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)

Who May Qualify: 1. Male or female aged at least 18 years old. 2. Capable of giving written consent on an IRB-approved willing to sign a consent form Form prior to any study-specific evaluation 3. Have a clinical diagnosis of SLE determined by the examining physician or a diagnosis of incomplete lupus determined by the examining physician 4. On a stable SLE treatment regimen consisting of a stable dosage of medications for a period of at least 30 days prior to testing Who Should NOT Join This Trial: 1. Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not related to SLE (i.e., diabetes, cardiovascular, pulmonary, hematologic, gastrointestinal, neurological, or infectious) which, in the opinion of the treating physician, could confound the results of the study or put the patient at undue risk 2. Have received intravenous glucocorticoids at a dosage of ≥ 500 mg daily within the past month 3. Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to Baseline 4. Pregnant or lactating. 5. Recent participation in a clinical trial with an experimental agent in the past 6 weeks, or 5 half-lives of the study drug, whichever is longer 6. Any condition that in the opinion of the treating physician might interfere with the performance of the LuGENE® test Always talk to your doctor about whether this trial is right for you.